T1	intervention 26 36	exemestane
T2	control 42 51	tamoxifen
T4	total-participants 986 989	371
T5	intervention-participants 1021 1024	182
T6	control-participants 1037 1040	189
T7	outcome 1153 1174	Overall response rate
T8	iv-bin-percent 1232 1235	46%
T9	cv-bin-percent 1238 1241	31%
T10	outcome 1295 1333	Median progression-free survival (PFS)
T11	cv-cont-median 1362 1372	9.9 months
T12	iv-cont-median 1423 1433	5.8 months
T13	eligibility 554 656	postmenopausal patients with measurable hormone-sensitive metastatic or locally advanced breast cancer
T3	outcome-Measure 1562 1565	PFS
T14	outcome 1648 1656	survival
